InflaRx Reports Third Quarter 2022 Financial & Operating Results
November 09, 2022 07:30 ET
|
InflaRx N.V.
Vilobelimab earns Orphan Drug and Fast Track designation for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients - Emergency Use Authorization (EUA) submitted to U.S....
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
September 29, 2022 07:30 ET
|
InflaRx N.V.
Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patientsEUA submission based on Phase III results in critically ill COVID-19 patients, recently published...
InflaRx to Present at Upcoming Scientific and Investor Conferences
September 09, 2022 07:30 ET
|
InflaRx N.V.
JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
September 08, 2022 07:30 ET
|
InflaRx N.V.
The Lancet Respiratory Medicine, a peer-reviewed journal, published the results of the PANAMO trial, one of the largest, global, 1:1 randomized, placebo-controlled Phase III studies conducted in...
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
July 06, 2022 07:30 ET
|
InflaRx N.V.
US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosumFast track follows recently reported orphan drug designation by both US FDA and EMA ...
InflaRx to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 07:30 ET
|
InflaRx N.V.
JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
May 12, 2022 07:30 ET
|
InflaRx N.V.
Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities...
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
March 31, 2022 07:30 ET
|
InflaRx N.V.
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary...
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
March 17, 2022 07:30 ET
|
InflaRx N.V.
JENA, Germany, March 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
March 08, 2022 07:30 ET
|
InflaRx N.V.
JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...